Discussion
In this phase 2 clinical trial, AP30663, a new KAmong currently existing drugs for pharmacological AF cardioversion, vernakalant and flecainide are the most efficaciousThe clinical efficacy of AP30663 aligns with the effects observed in animal models, where AP30663 showed a pronounced effect on the atrial effective refractory period in one pig model, and successfully cardioverted AF and prevented its reinduction in another pig model where vernakalant did not cardiovert any longerAP30663 inhibits the KThe safety profile of AP30663 was consistent with results from the phase 1 trial, with the exception that infusion site reactions were reported in the phase 1 trial whereas none were reported in the current trialExisting drugs with different mechanisms of action, when effective in AF cardioversion, also show efficacy in sinus rhythm maintenance (prevention of AF recurrence)This trial has some limitations. We enrolled patients with an AF episode lasting less than 7 days. Other drugs have shown decreased efficacy with longer AF durationsIn conclusion, the K